Research Article

FRL: An Integrative Feature Selection Algorithm Based on the Fisher Score, Recursive Feature Elimination, and Logistic Regression to Identify Potential Genomic Biomarkers

Chenyu Ge, Liqun Luo, Jialin Zhang, Xiangbing Meng, and Yun Chen

1School of Mechanical, Electrical, & Information Engineering, Shandong University, Jinan 250000, China
2Department of Information Management, Peking University, Beijing 100000, China
3Laboratoire de Recherche en Informatique, Paris-Saclay University, Paris 91405, France
4Qufu Institute of Traditional Chinese Medical Health and Rehabilitation, Qufu 273100, China
5The Second Hospital Affiliated to Shandong University of TCM, Jinan 250000, China

Correspondence should be addressed to Chenyu Ge; 201800800274@mail.sdu.edu.cn

Received 22 April 2021; Accepted 21 May 2021; Published 14 June 2021

Academic Editor: Tao Huang

Copyright © 2021 Chenyu Ge et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Accurate screening on cancer biomarkers contributes to health assessment, drug screening, and targeted therapy for precision medicine. The rapid development of high-throughput sequencing technology has identified abundant genomic biomarkers, but most of them are limited to single-cancer analysis. Based on the combination of Fisher score, Recursive feature elimination, and Logistic regression (FRL), this paper proposes an integrative feature selection algorithm named FRL to explore potential cancer genomic biomarkers on cancer subsets. Fisher score is initially used to calculate the weights of genes to rapidly reduce the dimension. Recursive feature elimination and Logistic regression are then jointly employed to extract the optimal subset. Compared to the current differential expression analysis tool GEO2R based on the Limma algorithm, FRL has greater classification precision than Limma. Compared with five traditional feature selection algorithms, FRL exhibits excellent performance on accuracy (ACC) and F1-score and greatly improves computational efficiency. On high-noise datasets such as esophageal cancer, the ACC of FRL is 30% superior to the average ACC achieved with other traditional algorithms. As biomarkers found in multiple studies are more reliable and reproducible, and reveal stronger association on potential clinical value than single analysis, through literature review and spatial analyses of gene functional enrichment and functional pathways, we conduct cluster analysis on 10 diverse cancers with high mortality and form a potential biomarker module comprising 19 genes. All genes in this module can serve as potential biomarkers to provide more information on the overall oncogenesis mechanism for the detection of diverse early cancers and assist in targeted anticancer therapies for further developments in precision medicine.

1. Introduction

Cancers are genomic diseases that cause uncontrolled abnormal cell growth through the constant accumulation of certain genetic mutations [1]. Genes that present specific regulation signals to activate corresponding signaling pathways in cancers are called genomic biomarkers and can be tested by DNA chips [2]. Traditional methods for cancer diagnosis concentrate on abnormalities in human organs and cells, which are intended to be error prone and time consuming as they depend on individual arbitration by an ultrasonic image diagnosis [3, 4]. Precision medicine is defined as the patient-targeted treatment based on the characteristics of genetic abnormalities and biomarkers. Currently, driven by the popularity of precision medicine [5], the goal of targeted therapies for cancers is to track and address biomarkers from multidimensional gene expression data [6].

The DNA chip is one of the applications of microarray technology. Chips can obtain gene expression data by synchronously tracking the expressions of a large number of genes. A gene expression profile has the characteristics of small sample sizes, high dimensionality, and large amounts...
of noise and redundancy. Feature selection algorithms can identify genomic biomarkers by selecting prominent subsets and classifying the chosen features [7]. The diagnosis and treatment of diverse cancers in biomedicine can be improved and the time required can be reduced by using feature selection algorithms [8].

Feature selection is a classic and effective method to filter out redundant features and form comprehensible models between the eigenvalues and vectors from a given dataset, and it can be categorized into three categories: filter, wrapper, and embedded algorithms [9]. Liang and Vucetic present a filter algorithm for feature selection that uses auxiliary microarray data [7]. Based on divergence or correlation indicators, filter methods function at the intrinsic properties of the dataset to reduce feature redundancy and increase the new classification information [10]. Typically, features with scores above a set threshold are selected. If there is no set of the threshold, the highest-scoring groups are extracted. As open-loop methods, filter methods have good universality and are faster than wrapper and embedded methods [11]. Piao et al. presents a wrapper method of the support vector machine to generate and evaluate subsets of genes [12]. Wrapper methods search feature subsets and perform iterative computation until optimal characteristic features are obtained. In terms of performances on the final model, wrapper methods are better than filter methods, but their calculation costs are high [13]. Embedded feature selection methods integrate the processes of feature selection and model training, which are automatically completed in the same optimization procedure. However, these algorithms are prone to overfitting, as the parameters need to be set to stop the training process at an appropriate time. Sun presents an ensemble scheme for simultaneously reducing dimensionality and extracting features, which greatly improves computational efficiency and accuracy [14]. Normally, an ideal feature selection scheme works as follows: filter algorithms are applied for reducing data dimensionality, and wrapper or embedded methods are further conducted for feature selection [15, 16].

In biomedical fields, diverse kinds of feature selection algorithms have been applied in extracting specific genomic biomarkers for targeted anticancer therapies [17, 18]. Ensemble classifiers can generally achieve greater precision and generalization ability than individual classifiers [19]. Biomarkers that are more reliable and reproducible, and reveal great potential on clinical application, can be more easily discovered through multiple analyses than through a single study [20]. In order to promote the classification capability of current feature selection methods, this paper creatively proposes a new feature selection algorithm named FRL by combining the advantages of filter methods and embedded methods (Figure 1). This method is implemented as follows: The original data are downloaded, and RMA is utilized to perform based on the R platform. Then, extensive gene extraction is performed on the feature space via a filtering method called Fisher score. Next, Recursive feature elimination and Logistic regression are conjointly utilized to select the relevant features and remove redundant features from the previous dataset in the embedded layer. Furthermore, the selected genes from a total of 10 datasets are grouped together, and ten datasets are compared in pairs and repeated genes on intersections are extracted. Lastly, validation of obtained gene groups is performed, and a genomic biomarker module is constructed through literature review and spatial analyses of functional enrichment and functional pathways.

The full thesis is structured as follows: Section 2 introduces the entire process of our novel FRL algorithm and the relevant validation method. In Section 3, the performance of our FRL is evaluated via four different methods, and esophageal cancer is the representative simulation scenario for comparison with Limma. The selected potential biomarkers in the biomarker module have been validated by diverse analyses in Section 3 as well. Section 4 and Section 5 present the discussion and conclusion.

2. Materials and Methods

2.1. Datasets. To validate the classification performance of the FRL and explore more reliable and reproducible potential biomarkers, we apply it to ten microarray gene expression datasets for cancers (GSE1420, GSE3325, GSE7696, GSE9750, GSE16088, GSE18520, GSE18842, GSE54129, GSE56315, and GSE65194). From among all cancer types, we selected the most common types of cancers that have high mortality, namely, lung cancer (21.5%), which is the leading cause of death among men, and breast cancer (15.5%), which is the leading cause for women death [21]. The qualities of these public gene expression datasets regarding diverse cancers are summarized in Table 1. All of the datasets are retrieved from a public repository called the Gene Expression Omnibus (GEO), which can be downloaded from the National Center for Biotechnology Information website (https://www.ncbi.nlm.nih.gov/).

2.2. Modulated Characteristics of the Gene Expression Data before Applying FRL. In the pretreatment step illustrated in the first column of Figure 1, we initially downloaded the original files of the gene expression data from the aforementioned database. A background correction method called the robust multiarray average (RMA), which eliminates more noise than other frequently used measures, such as the model-based expression index (MBEI) [35], is applied to the datasets through the bioconductor package on the R platform. The aim of background correction is to remove the effect of the labeled probe on gene expression by binding it to a non-specifically labeled DNA molecule. During this process, because of the diverse regions included in genes, which will directly lead to different probe signals corresponding to certain genes, the number of genes is often slightly less than the number of probes. In allusion to this, we first averaged the probe groups corresponding to a given gene and then choose the largest probe group as the representative to match with the corresponding gene. Then, according to the reference sequences in the public nucleic acid database, a matrix with samples and gene expression data is constructed. Normalization and summarization are performed on matrices for subsequent feature selection. In addition, the gene expression data are transformed into the form of $\log_2$ to reduce calculation complexity.
2.3. Integrative Feature Selection Scheme (FRL) for Identifying Multiple Genomic Biomarkers. Because of the curse of dimensionality, the high-dimensional data from gene expression profiles present challenges for the use of traditional feature selection methods, including overfitting, weak generalization ability, and high variance [36]. The relationship between the samples and features of the cancer datasets is formulated by the following matrix:

\[
\begin{align*}
    x_1 &= (x_{11}, x_{12}, x_{13}, \cdots, x_{1n}) \; ; \; y_1 \\
    x_2 &= (x_{21}, x_{22}, x_{23}, \cdots, x_{2n}) \; ; \; y_2 \\
    x_3 &= (x_{31}, x_{32}, x_{33}, \cdots, x_{3n}) \; ; \; y_3 \\
    \vdots & \quad \vdots \\
    x_m &= (x_{m1}, x_{m2}, x_{m3}, \cdots, x_{mn}) \; ; \; y_m
\end{align*}
\]

where \( x_m \) is defined as the \( m \) link of the characteristic vector, and \( y_m \) describes the column vector representing the sample categories. Typically, in the machine learning field of a supervised pattern, every \( x_m \) is matched with a compatible labeled \( y_m \); the feature selection methods in a supervised pattern are aimed at deducing the proper function that can describe the relationship between \( x_m \) and \( y_m \). Furthermore, the function can suggest the main influencing factor in the original data. Thus, it is vital to propose an effective and robust feature selection method.

To precisely extract genomic biomarkers, we designed an integrative algorithm called FRL. This method is applied on the ten abovementioned cancer datasets. The aim of the FRL algorithm is to focus on dimensionality reduction and sift the optimal subset for further selection of genomic biomarkers. In this method, the scores of each feature are initially computed and ranked based on Fisher score evaluation system; after ranking the scores of genes in descending order, new subsets with high-score genes are formed for each type of cancer. Recursive feature elimination and Logistic regression are cooperatively used to improve the precision of subsets in the next feature selection round. Then, the most ideal subset among the obtained subsets is selected based on relevant measures. Finally, genes are classified into biomarker modules by literature review and spatial analysis of functional enrichment. These processes will be elaborated below in detail. Procedure 1 presents the entire process of the FRL feature selection method.

### Table 1: Introduction of the gene expression data on 10 cancers.

| ID       | Dataset                           | Cancer | Normal | References |
|----------|-----------------------------------|--------|--------|------------|
| GSE1420  | Esophageal                        | 8      | 16     | [22]       |
| GSE3325  | Prostate                          | 6      | 13     | [23]       |
| GSE7696  | Glioblastoma                      | 80     | 4      | [24, 25]   |
| GSE9750  | Cervical                          | 33     | 24     | [26]       |
| GSE16088 | Osteosarcoma                      | 14     | 6      | [27]       |
| GSE18520 | Ovarian                           | 53     | 10     | [28]       |
| GSE18842 | Lung                              | 46     | 45     | [29]       |
| GSE54129 | Gastric                           | 111    | 21     | [30]       |
| GSE56315 | Diffuse large B-cell lymphoma     | 55     | 33     | [31, 32]   |
| GSE65194 | Breast                            | 153    | 11     | [33, 34]   |

![Figure 1: Each rectangle represents a dataset. In the first step, pretreatment on original data is performed. The filter layer performs gene extraction and removes redundancy. The embedded layer is utilized to accurately extract the relevant features from the last step. The selected genes are then grouped to form a genomic biomarker module and are validated through diverse methods.](image-url)
Method: FRL  
Input: Gene expression original matrix $M = \{ (x_i, y_i) \}_{i=1}^m$  
Output: Gene subset $S$  
For $n$ in 1:10  
Pretreat and Apply Robust Multi-Array average to remove the effect of labeled probes on real gene expression and form matrix $A, B, C, D, E, F, G, H, I, J$  
End  
For $i$ in 1:$N$  
Calculate the fisher score $x_i$ of $A$ based on formula (Equation (2))  
End  
Divide the same maximum number features as one cluster. Spot the inflection point and extract the abundant data. Name new matrix as $A_1$  
Set up the iteration step $P$ and $K$ according to diverse dimension $D_1$  
For $x$ in 1 : $P : D_1$  
For $x$ in 1 : $K$-fold  
Train recursive feature elimination model with logistic regression classifier in $A_1^{'}_{\text{train}}$  
Calculate accuracy (ACC) in $A_1^{'}_{\text{test}}$  
Use $K$-fold cross validation to calculate average ACC  
End  
End  
Obtain the current dimension $D_1$ with the optimal performance ACC  
Select the feature subset according to $D_1$ to make $A_2$ matrix  
Extract the repeated genes from $A_1, B_1, C_1, D_1, E_1, F_1, G_1, H_1, I_1, J_1$ and make a new matrix  
Obtain final feature subset $S$.  

Procedure 1: Procedures of FRL (mainly illustrated by Amatrix).

2.3.1. Filter Layer: Use Fisher Score to Identify and Delete Redundant Features and Enhance the Quality of Training Datasets. The filter method is implemented as follows: A threshold or correlation coefficient is set as an evaluation criterion by the tester(s), and then the genes of identical quality are extracted based on specific penalty functions and used to form brand-new subsets. This filter mechanism accelerates the speed and performance of classification by converting data with high dimensionality to binary classification problems. In the supervised feature selection field, the formula of Fisher score is defined as follows:

$$F(x_i) = \frac{\sum_{k=1}^{c} n_k (\mu_k^i - \mu^i)^2}{(\sigma^i)^2} \quad (2)$$

The equation uses $c$ to represent the total number of categories. $n_k$ refers to the sample amount of the $j$ class. $\mu_k^i$ and $\mu^i$ indicate the mean values of the $j$ class and the mean values of the current gene expression level, respectively. $\sigma^i$ denotes the variance value of the $j$ class across the whole dataset. Fisher score is employed as the evaluation standard in a filter layer. The scores of each sort can be calculated by equation (2). All genes within the same dataset are scored and arranged in descending order. We identify the inflection point of each cancer category, extract the data before this point to form a subset, and construct matrix $A_1$. The dimension $D_1$ of the present matrix is reduced to 1593 averagely from the initial dimension of 21654. This procedure can produce a high-quality output, even with poor computing power.

2.3.2. Embedded Layer: Employ Recursive Feature Elimination and Logistic Regression to Narrow Down the Feature Space. High generalization ability is the core criterion used to identify whether a supervised learning algorithm is effective. Ensemble algorithms can be more effective than a single algorithm to achieve this standard. Thus, here, Recursive feature elimination and Logistic regression are jointly utilized to traverse the whole feature space. In this step, the iteration pace $P$ varies from 2 to 5 and is established based on the dimensionality $D_1$ of each cancer. We set 5 for a dataset that has a dimension of over 2000, 3 for a dataset that has a dimension of over 1000 but less than 2000, and 2 for a dataset that has a dimension of less than 1000. Simultaneously, we divide matrix $A_1$ into $K$ pieces to perform cross validation. The index $K$ is set based on the dimensionality $D_1$ of either data set. If $K$ is set as 4, the whole dataset will be divided into 4 pieces. The $K$-fold cross validation will orderly extract one as a test set among 4 sets, leaving the other 3 pieces as a training set for the training model and classifier.

Recursive feature elimination is a typical backward reduction algorithm. However, it cannot be used alone and must be implemented with appropriate classifiers. Recursive feature elimination processes as follows: Firstly, certain classifiers are combined with Recursive feature elimination to train the $A_1^{'}_{\text{train}}$. Next, the value of each feature is calculated and irrelevant features are eliminated. Then, the dataset is automatically reconstructed and values for features are calculated again until the optimal feature subsets are obtained.

Logistic regression is applied as the classifier for Recursive feature elimination to determine the probability in each category. Logistic regression is a generalized linear algorithm on binary classification. It is based on the linear regression
model and sigmoid function. Hypothesize the linear function as follows:

\[ g(x) = \omega^T x + b. \]  

The sigmoid function can be defined by formula (4), and the logistic regression can be defined by formula (5):

\[ \varphi(j) = \frac{1}{1 + e^{-\omega^T x + b}}, \]
\[ \varphi(x) = \frac{1}{1 + e^{-\omega^T x + b}}. \]

The cost function, which can be used to measure the quality of the Logistic regression model is listed as follows:

\[ J(\omega, b) = \frac{1}{m} \sum_{i=1}^{m} (-y \ln a + (1 - y) \ln (1 - a)). \]  

In equation (6), \( a \) denotes the probability that is calculated by Logistic regression. \( y \) represents the label of this sample, and there is a total of \( m \) samples. The aim for Logistic regression is to reduce the outcome of function (6) as much as possible via iteration. Through the use of multiple samples to fit the Logistic regression model for several times, the important features can be filtered out. After the above processes are completed, we obtain the matrix \( A_j \) and sort all of the matrices obtained in this step on 10 cancers into corresponding S subsets. Finally, we validate the existing genes and form a biomarker module through meta-analysis in a biomedical field.

2.4. Performance Evaluation. Four evaluation indexes are applied to evaluate method performance. A confusion matrix is used to compute and output four types of records. False Negative (FN) represents the number of positive samples predicted as negative samples; False Positive (FP) represents the number of negative samples predicted as positive samples; True Negative (TN) represents the number of negative samples predicted as negative samples; True Positive (TP) represents the number of positive samples predicted as positive samples. The following equations demonstrate the calculation of common indicators based on TP, TN, FP, and FN:

- **Accuracy**: \( \text{ACC} = \frac{TP + TN}{TP + FN + FP + FN} \),
- **F1-score**: \( F_1 = \frac{2TP}{2TP + FP + FN} \),
- **Precision**: \( \text{PRE} = \frac{TP}{TP + FP} \).

Heat maps are presented to test the validation of selected genomic biomarkers of the FRL model. The efficiency level of features is reflected in the sharp edges of the heat map. The heat maps are constructed based on the rationale of the Euclidean distance with the `ggplot2` package on the R platform. By clustering measurements of samples in Euclidean distance, the clustering results of samples are obtained. \( X_{MN} \) and \( Y_{MN} \) denote two matrices, in which the rows and columns are indexed by \( i \) and \( j \). The calculation of Euclidean distance is presented as follows:

\[ d(x_i, y_j) = \sqrt{\|x_i\|^2 + \|y_j\|^2 + 2x_i y_j}. \]

3. Results

3.1. Validation for Oncology Datasets via Diverse Indicators. The first column in Figure 1 displays the initial dataset and the same dataset that has been processed by the RMA method. Compared with the initial dataset, the pretreated datasets obviously exhibit high concentrations and are prone to discover an intrinsic relationship among genes.

Figure 2(a) exhibits the Fisher score values in a descending order, from which we can observe an obvious inflection point in each subimage. Figure 2(b) presents the distribution of genes with diverse scores in a more visible way. It is obvious that the genes with high scores only account for a tiny fraction among the whole dataset. As listed in Table 2, only a tiny quantity of genes remain, which demonstrates that Fisher score can rapidly and effectively reduce the dimensionality.

The 2-NUM column in Table 2 displays the results for the step of feature selection in the embedded layer. This outcome has higher accuracy and precision parameters than those in the previous filter step. A series of genes are consequently selected from the recurring data, and the ultimate output is shown below in Table 3. The relevant performance of each subset is examined. Through literature review and spatial analysis of functional enrichment and functional parameters, a biomarker module is formed.

To validate the capability of the biomarker module, Euclidean distance matrices are adopted for clustering based on GSE3325, GSE7696, GSE54129, and GSE56315. We can directly observe that the subset obtained after feature selection clearly delimits the area (Figure 3). Thus, the final subset can be key features to represent each cancer dataset.

To prove the validity of the FRL feature selection method on a single cancer, the diverse datasets of esophageal cancer (GSE1420, GSE23400) are chosen as representative datasets. GSE1420 is treated as the training set, and GSE23400 [37]
is treated as the test set. We use genes selected by FRL on the esophageal dataset to examine the indicators of generalization ability through four main classifiers. Figure 4 shows the receiver operating characteristic (ROC) curve and the area under the ROC curve (AUC), which is an effective and intuitive measure for evaluating feature selection classification performance. The AUC is more than 93% on three classifiers and the average AUC reaches 92%, obviously indicating that the generalization ability of the biomarker module is satisfied.

In addition, we build an isolated environment by dividing another dataset of esophageal cancer (GSE26886) into a test set to examine the indicators of generalization ability through four main classifiers. Figure 4 shows the ROC curve and the AUC, which is an effective and intuitive measure for evaluating feature selection classification performance. The AUC is more than 93% on three classifiers and the average AUC reaches 92%, obviously indicating that the generalization ability of the biomarker module is satisfied.

Table 2: Performance measures of the original dataset, the first round, and the second round.

| ID     | 0-ACC | 0-NUM | 1-ACC | 1-F1-score | 1-NUM | 2-ACC | 2-F1-score | 2-NUM |
|--------|-------|-------|-------|------------|-------|-------|------------|-------|
| GSE1420| 62.50%| 12549 | 100%  | 100%       | 1803  | 100%  | 100%       | 78    |
| GSE3325| 83.33%| 21654 | 83.33%| 75.76%     | 1302  | 100%  | 100%       | 69    |
| GSE7696| 96.15%| 21654 | 100%  | 100%       | 1803  | 100%  | 100%       | 65    |
| GSE9750| 65.00%| 21654 | 90.00%| 89.52%     | 1403  | 100%  | 100%       | 78    |
| GSE16088| 66.67%| 12549 | 83.33%| 85.19%     | 2003  | 100%  | 100%       | 78    |
| GSE18520| 89.47%| 21653 | 100%  | 100%       | 753   | 100%  | 100%       | 50    |
| GSE18842| 57.14%| 21654 | 71.43%| 69.60%     | 3453  | 96.43%| 100%       | 77    |
| GSE54129| 85.00%| 21654 | 85.00%| 78.11%     | 1011  | 100%  | 100%       | 77    |
| GSE56315| 96.30%| 21654 | 100%  | 100%       | 1603  | 100%  | 100%       | 78    |
| GSE65194| 94.00%| 21654 | 100%  | 100%       | 801   | 100%  | 100%       | 79    |
set and a training set. 35% of the samples in GSE26886 [38] are randomly chosen to construct the training set. The remaining samples are utilized as the test set. Figure 5 presents the ROC curve of each fold. Three of the classifiers reach a value of 0.99 on areas under the ROC curve (AUC), and the average Gini index on four classifiers is 0.97, which effectively implies that the potential genomic biomarkers selected by FRL may have strong associations with cancers.

Breast cancer (GSE65194) is chosen as another representative to examine the validation of FRL classification performance. CREBBP, EP300, ESR1, GATA3, and MYC are well-known genetic biomarkers and mutate frequently in breast tumors [39]. These five approved genetic biomarkers on breast cancer are compared with the same amount of potential biomarkers selected by FRL. Figure 6 displays the Precision-Recall (P-R) curve. The AUC of the five known biomarkers is 93.2%. The AUC of FRL can be 6.8% higher than those on the five mentioned biomarkers. It is meaningful and feasible to develop further clinical experimental verification on potential genomic biomarkers selected by FRL.

### Table 3: Performance indicators on the final subsets for diverse cancers.

| ID       | Dataset                        | Gene-num | PRE   | ACC   | F1-score |
|----------|--------------------------------|----------|-------|-------|----------|
| GSE1420  | Esophageal                     | 5        | 89.58%| 87.50%| 86.82%   |
| GSE3325  | Prostate                       | 2        | 100%  | 100%  | 100%     |
| GSE7696  | Glioblastoma                   | 3        | 92.46%| 96.15%| 94.27%   |
| GSE9750  | Cervical                       | 5        | 92.22%| 90%   | 90.21%   |
| GSE16088 | Osteosarcoma                   | 4        | 100%  | 100%  | 100%     |
| GSE18520 | Ovarian                        | 2        | 96.49%| 94.74%| 95.18%   |
| GSE18842 | Lung                           | 3        | 91.29%| 89.29%| 89.24%   |
| GSE54129 | Gastric                        | 3        | 100%  | 100%  | 100%     |
| GSE56315 | Diffuse large B-cell lymphoma  | 4        | 100%  | 100%  | 100%     |
| GSE65194 | Breast                         | 3        | 100%  | 100%  | 100%     |

**Table 3:** Performance indicators on the final subsets for diverse cancers.

3.2. Comparisons between FRL and Other Feature Selection Methods. To compare with the differential expression analysis tool GEO2R based on Limma, esophageal cancer (GSE26886) is chosen as the representative. Figure 7 displays the classification results on Limma by ROC curve in each fold, and the average AUC is 96.25%. It is 2.25% lower than the genes selected by FRL. On classification precision, the FRL algorithm can reach 95.56%, while Limma can only reach 91.11%. In order to obtain persuasive data, 10-fold cross validation is looped 20 times. The average ACC and

![Figure 3: (a) Heat map of original matrix. (b) Heat map of the matrix that uses the Euclidean distance to cluster.](image-url)
F1-score of FRL are 96.24% and 96.37%, respectively. And the average ACC and F1-score of Limma are 96.04% and 95.91%, respectively. FRL is 0.2% and 0.46% superior to Limma. When looped 100 times, the metrics of FRL on ACC reaches 96.32% and can still reach 0.1759% higher than Limma. It is obvious that FRL has greater classification precision than the current differential expression analysis tool GEO2R based on the Limma algorithm on the GEO platform.

The following five methods are used for making comparisons with the FRL feature selection algorithm in terms of their ACCs and F1-scores (Figure 8): Ridge regression (Ridge), Extremely randomized trees (Extra Trees), Random Forest, Lasso, and Lasso-Logistic regression. Since there are only a few genes that have significance to carcinogenesis and can be regarded as biomarkers, by repeated experiments, we found that when the context confines the size of subset to approximately 80, it can achieve perfect classification capability. To follow variable-controlling approaches, 78 is chosen as the standard dimensionality for genes in all the subsets for all the participating methods being used as a comparison.

Table 4 lists the final prediction results of the aforementioned methods. Focusing on certain particularly low-quality datasets, such as GSE1420 (esophageal) and GSE18842 (ovarian), we summarize that the ACCs of FRL are 30% and 17.622%, respectively. These values are much higher than those of the other traditional algorithms. Regarding the average statistics (Table 4), it is clear that FRL is 10.01% and 10.428% superior to other traditional methods in terms of their average ACC and F1-score, respectively. Compared to the Lasso-Logistic regression, which is a current principal feature selection method for effective dimensionality reduction, FRL can be 5.464% and 4.534% higher than it on ACC and F1-score, respectively.

As GSE18842 (ovarian) has the highest dimensionality after the selection in a filter layer and may consume the longest time in the embedded layer, FRL and the abovementioned five methods are applied on GSE18842 (ovarian) to test the time consumed in the whole feature selection process. In order to follow variable-controlling approaches, the final subset dimensionality is restricted to 78 for all methods. As
data shown in Table 5, FRL consumes only 79.619 s and can be at least three times faster than the second fastest method Lasso. However, Lasso displays low performance on ACC and F1-score. Compared to the method with approximate ACC, FRL calculates 52 times faster than Random Forest. Obviously, FRL can greatly decrease computation time, accelerate computation speed, and improve computation efficiency.

In general, an obvious and intuitive conclusion is that FRL exhibits better performance relative to current website analysis tools and other traditional feature selection methods. Compared with FRL, the conventional feature selection algorithms extract and establish unreliable and frail subsets, which may result from inappropriate performance of metrics, unbalanced labels for the dataset, and low noise immunity in the models themselves. For the remaining tested datasets, FRL also shows unique robustness, high precision, and stable classification capability.

3.3. A Functional Analysis of the Biomarker Module. The 19 genes in the biomarker module are as follows: ALPI, AMACR, ANKHD1, ARHGAP44, ARHGECF15, ARHGECF26, ATXN8OS, CRISP3, HOPX, HSPB8, LSM7, MAFB, NGRN, PPP3RI, RDH5, SLC5A1, SPARC, SPRR3, and TCTN2. Initially, we corroborate genes in the biomarker module through the following four approaches: CCLE (the Cancer Cell Line Encyclopedia, https://portals.broadinstitute.org/ccle), COSMIC (the Catalogue Of Somatic Mutations In Cancer, https://cancer.sanger.ac.uk/cosmic), NCG (the Network of Cancer Genes, https://ncg.kcl.ac.uk/index.php), and literature reviews. To depict the hereditary characteristics of cancer cells, the CCLE project has cooperated with the Broad Institute, Dana Farber Cancer Institute, and Novartis Institute. CCLE exhibits expression of genes in diverse tumor cell lines, and all the genes in our biomarker module can be found in it. COSMIC has been a neutral worldwide reference standard as it provides a comprehensive and detailed introduction for over 700 mutated genes. [40, 41]. The NCG is a database of tumor-driven genes and includes cancer information, orthology, and gene expressions in normal tissues. Furthermore, the literature is also searched to
Figure 6: (a) The P-R curve of classification results by the five approved genetic biomarkers on GSE65194. (b) The P-R curve of classification results by potential genetic biomarkers selected by FRL on GSE65194.

Figure 7: The results of another esophageal dataset (GSE26886) in the form of an ROC curve by Limma are visualized.
confirm the validation of the 19 genes in total, which introduces the detailed function and potential carcinogenic pathways of the above 19 genes. Table 6 apparently shows associations between the biomarker module and various cancers.

To further explore the basic biological functions of the biomarker module, cluster-Profiler from the R platform is used to perform a Gene Ontology (GO) analysis. The results concentrate in the range of $P < 0.05$, as shown in Figure 9. $P < 0.05$ is a statistics standard to denote that selected objects own significant difference. These 19 genes are mainly enriched with these three functional pathways: regulation of synapse organization, regulation of synapse structure or activity, and regulation of Ras protein signal transduction ($P < 0.0015$). These pathways are relative to the regulation of cellular component organizations and related protein expressions, which are consistent with the characteristics that cancer cells perform invasive and expansionary growth to the surrounding tissue. More detailed statistics are provided in the supplementary materials.

Through analysis of the biomarker module, we classify the genes into two main categories. The initial category, containing ANKHD1, ATXN8OS, HSPB8, LSM7, MAFB, and TCTN2, is involved in the direct regulation of cancer cell proliferation, apoptosis, and canerization. We discovered that a single biomarker in this category can activate various signaling pathways in different cancers. For instance, ANKHD1 is an ankyrin-repeat-containing gene involved in the regulation of a variety of cellular functions, including transcription, cell cycling, ion channels, cell survival, and cell signaling pathways. ANKHD1 is expressed in the cytoplasm or nuclei of different tissues. In prostate cancer cell lines, ANKHD1 is a positive regulator of YAP1 and promotes cell growth and cell cycle progression by promoting cyclin A [42]. In the K562 line of leukemia cells, ANKHD1 acts as a skeleton protein and affects its malignant phenotype by interacting with SHP2 [43]. In human multiple myeloma cell lines, ANKHD1 can act on the promoter region of the cyclin-dependent kinase inhibitor p21 to upregulate the proliferation of multiple myeloma cells and affect the cell cycle progression [44].

Another example is HSPB8. As a gene involved in the heat shock protein family, HSPB8 is ubiquitously expressed in a variety of human tissues. In triple-positive hormone-sensitive breast cancer cell lines (MCF-7), HSPB8 regulates the proliferation and reduction of the migratory ability for MCF-7 cells [45]. In ovarian cancer cell lines, the downregulation of HSPB8 positively directs the migration progress of the transforming growth factor alpha (TGF-α) for ovarian cancer cells [46]. HSPB8 is detected to be overexpressed in
| Indicators | FRL | Ridge | Extra Trees | Random Forest | Lasso | Lasso-Logistic regression | Average of the other methods |
|------------|-----|-------|-------------|---------------|-------|---------------------------|----------------------------|
| GSE1420    | 100 | 100   | 75          | 70.83         | 62.5  | 75                        | 75                         |
| GSE3325    | 100 | 100   | 83.33       | 66.67         | 100   | 100                       | 96.15                      |
| GSE7696    | 100 | 100   | 96.15       | 94.27         | 100   | 94.27                     | 94.27                      |
| GSE9750    | 100 | 94.9  | 66.67       | 84.7          | 96.15 | 89.52                     | 96.15                      |
| GSE16088   | 95  | 100   | 90          | 100           | 100   | 95.18                     | 95.18                      |
| GSE18520   | 100 | 100   | 85          | 85            | 90    | 83.33                     | 95.47                      |
| GSE18842   | 100 | 92.86 | 85          | 85.57         | 95    | 89.24                     | 89.24                      |
| GSE54129   | 100 | 100   | 85          | 85            | 100   | 85                        | 85.11                      |
| GSE56315   | 100 | 100   | 100         | 98            | 98    | 97.81                     | 97.81                      |
| GSE65194   | 100 | 100   | 100         | 98            | 98    | 98                        | 98                        |
| Average    | 99.5| 98.77 | 90.563      | 88.77         | 89.917| 88.36                     | 95.004                     |
Table 5: Comparisons between FRL and five other feature selection algorithms on time consumption.

| Algorithm       | Time consumption |
|-----------------|------------------|
| FRL             | 79.619 s         |
| Ridge           | 3328.9418 s      |
| Extra Trees     | 2690.1589s       |
| Random Forest   | 4148.396 s       |
| Lasso           | 263.944 s        |
| Lasso-Logistic regression | 264.042 s |

Table 6: Metavalidation results of selected genes.

| Gene       | CCLE | Literature | COSMIC | NCG |
|------------|------|------------|--------|-----|
| ALPI       | ✓    | ✓          | ✓      | ✓   |
| AMACR      | ✓    | ✓          | ✓      | ✓   |
| ANKHD1     | ✓    | ✓          | ✓      | ✓   |
| ARHGAP44   | ✓    | ✓          | ✓      | ✓   |
| ARHGFEF15  | ✓    | ✓          | ✓      | ✓   |
| ARHGFEF26  | ✓    | ✓          | ✓      | ✓   |
| ATXN80S    | ✓    | ✓          | ✓      | ✓   |
| CRISP3     | ✓    | ✓          | ✓      | ✓   |
| HOPX       | ✓    | ✓          | ✓      | ✓   |
| HSPB8      | ✓    | ✓          | ✓      | ✓   |
| LSM7       | ✓    | ✓          | ✓      | ✓   |
| MAFB       | ✓    | ✓          | ✓      | ✓   |
| NGRN       | ✓    | ✓          | ✓      | ✓   |
| PPP3R1     | ✓    | ✓          | ✓      | ✓   |
| RDH5       | ✓    | ✓          | ✓      | ✓   |
| SLC5A1     | ✓    | ✓          | ✓      | ✓   |
| SPARC      | ✓    | ✓          | ✓      | ✓   |
| SPRR3      | ✓    | ✓          | ✓      | ✓   |
| TCTN2      | ✓    | ✓          | ✓      | ✓   |

Gastric cancer, and it regulates the proliferation and apoptosis progress of gastric cells by activating the ERK- CREB signaling [47].

The second category contains protein-coding genes, namely, ALPI, ARHGFEF15, ARHGFEF26, SLC5A1, AMACR, ARHGAP44, CRISP3, HOPX, NGRN, RDH5, SPRR3, and PPP3R1, which indirectly play significant roles in the regulation progress of proteins. Mutations in these genes impact protein expression levels and further lead to the development of prostate, breast, and colorectal cancers, as well as other cancer types. For example, ARHGFEF15 regulates the activation of Rho family proteins. As essential signaling molecules, Rho family proteins modulate gene expression progress, cell motility progress, cell cycles, and other processes by regulating downstream molecules such as p21-activated kinase (PAK) and the myosin-binding subunit of myosin phosphatase (MYPT1) [48]. The transcripts of CRISP3 are widespread in human glands such as the prostate. CRISP3 induces the abundant changes in the cell adhesion protein subsets Laspi and TJP1, which are included both in in vitro and in vivo environments, and CRISP3 can therefore promote the development of tumors in the prostate [49]. The overexpression of HOPX, upregulation of p21, and downregulation of cyclin D1 and CDK4 regulate the progress of migration and invasion of MDA-MB-468 cells to modulate tumor growth of the breast [50]. Colorectal cancer (CRC) is an example where the expression of SPRR3 promotes the binding between PCAT18 and miR-759 and therefore restores a portion of the proliferation and invasion capabilities of CRC cells [51]. The combination of GO analysis and the literature review directly displays the connection between the proposed biomarker module and diverse cancers.

4. Discussion

The high cost and low reproducibility of microarray experiments make it arduous for experimental researchers to identify common genomic biomarkers of the same type of cancer [52]. Research reflects that tumors with similar phenotypes or representing the same type of cancer can have diverse responses to the same treatment, which may result from differences in gene expression [53]. By combining all the separate cancer datasets described above, highly universal clues can be summarized and missing important clustering details can be avoided, thereby enhancing the accuracy of the algorithm as well as revealing the gene expression mechanism [54].

The first contribution of this paper is the introduction of the FRL feature selection method. The FRL framework can effectively screen out robust genes with high accuracy. The traditional filter method, which aims at acquiring and removing redundant features, is not useful for extracting robust subsets of cancers. This paper uses Fisher score to screen subsets in the filter layer, and it mainly depends on human judgment to choose the optimal subset. A deficiency in the filter layer is the threshold setting requirement. In practice, the subset selected by human judgment will differ from the optimal subset. Therefore, in the future, we could explore more algorithms to obtain accurate calculations of the threshold, thereby enhancing flexibility and adaptability. In addition, Fisher score is effective for selecting high-score features. Thus, it is possible that some biomarkers with low scores are ignored in the selection process. In the future, we can pay more attention to low-score genes, which would be beneficial for the thorough exploration of certain cancers.

The second contribution of this paper is the effective extraction of genes to form a biomarker module based on 10 cancers associated with high mortality. Cluster studies can be beneficial in revealing the core mechanisms of high-mortality cancers [53]. Through GO analysis and multiple literature review, all the genes in this module have been verified to be related to diverse cancers. Furthermore, details of some of the pathways involving these genes have been obtained. The biomarker module tends to provide a range of genes that have great performances. It could overcome the difficulty of single genes, i.e., it is hard for a single gene to recur on gene chips; therefore, this narrows down the selection scope for clinical researchers. However, there is still a limitation for directly applying potential biomarkers in our module on a single type of cancer. With comprehensive
information obtained from cluster studies on multiple data-
sets, we can combine calculated data with clinical data,
whole-genome sequencing, and the use of gene expression
atlases to further explore the types and sites of gene muta-
tions for single types of cancer in the future, which can attach
great significance to the development of the health evalu-
ation of ultra-early cancers associated with high mortality, the
evaluation of radiotherapy e
cacy, the prediction of the e-
cacy of target drugs, and monitoring for early postoperative
recurrence of single types of cancers in precision medicine.

Furthermore, we can upload our biomarker module data
to a public database for other researchers to download,
which can overcome drawbacks such as data de
ciciency and accelerate the identiﬁcation process of all cancer bio-
markers in Homo sapiens.

5. Conclusions
We present an integrative feature selection algorithm called
FRL, which employs Fisher score, Recursive feature elimina-
tion, and Logistic regression (FRL). It has greater precision
performance than differential expression analysis tools based
on Limma and five traditional feature selection methods.
Time consumption has also been reduced through compari-
son with the abovementioned ﬁve methods. With the help of
this method, we screened 19 genes from a total of 189224
genes in 10 high-mortality-cancer datasets to form a bio-
marker module. Via GO analysis and multiple meta-
analysis in the biological ﬁeld, all genes in this module are
proven capable of serving as potential biomarkers of the reg-
ulation of cancer cellular component organization or related
protein expressions, which corresponds to the characteristics
that cancer cells perform invasive and expansionary growth
to the surrounding tissue. This module is bene
cial to health
assessment, drug screening, and targeted therapy. In addi-
tion, the selected potential biomarker module can supply
information on the development of cancers with high
mortality, which assists in precision medicine.

Data Availability
The datasets for this study (GSE1420, GSE3325, GSE7696,
GSE9750, GSE16088, GSE18520, GSE18842, GSE54129,
GSE56315, GSE65194, GSE26886 and GSE23400) can be
found in https://www.ncbi.nlm.nih.gov/. The code of FRL can be found in https://github.com/jianan-kristine/code.git.

**Conflicts of Interest**

We declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Supplementary Materials**

*Supplementary 1.* Additional 1 presents the values of performance indicators of the selected model for esophageal cancer (GSE26886).

*Supplementary 2.* Additional 2 shows more detailed statistics for the P value which is less than 0.01 of GO analysis on the functional path in Figure 9.

**References**

[1] O. Podlaha, M. Riester, S. De, and F. Michor, "Evolution of the cancer genome," *Trends in Genetics*, vol. 28, no. 4, pp. 155–163, 2012.

[2] I. J. Majewski and R. Bernards, “Taming the dragon: genomic biomarkers to individualize the treatment of cancer,” *Nature Medicine*, vol. 17, no. 3, pp. 304–312, 2011.

[3] K. R. Kavitha, A. Prakasan, and P. J. Dhriti, “Score-based feature selection of gene expression data for cancer classification,” in *2020 Fourth International Conference on Computing Methodologies and Communication (ICCMC)*, Erode, India, 2020.

[4] R. Nussinov, H. Jang, G. Nir, C. J. Tsai, and F. Cheng, “A new precision medicine initiative at the dawn of exascale computing,” *Signal Transduction and Targeted Therapy*. vol., vol. 6, no. 1, p. 3, 2021.

[5] J. Larry Jameson and D. L. Longo, “Precision medicine—personalized, problematic, and promising,” *Obstetrical & Gynecological Survey*, vol. 70, no. 10, pp. 612–614, 2015.

[6] M. Francisco, F. Muinos, D. P. J. Inês Sentis, and N. Lopez-Bigas, “A compendium of mutational cancer driver genes,” *Nature reviews Cancer*, vol. 20, pp. 555–572, 2020.

[7] L. Liang and S. Vucetic, “Improving accuracy of microarray classification by a simple multi-task feature selection filter,” *International Journal of Data Mining and Bioinformatics*, vol. 5, pp. 189–208, 2011.

[8] S. F. Farahbakhshian and M. T. Ahvanooye, “A new gene selection algorithm using fuzzy-rough set theory for tumor classification,” *Control Engineering and Applied Informatics*, vol. 22, no. 1, pp. 14–23, 2020.

[9] I. Guyon and E. André, “An introduction of variable and feature selection,” *Journal of Machine Learning Research*, vol. 3, pp. 1157–1182, 2003.

[10] C. Lazar, “A survey on filter techniques for feature selection in gene expression microarray analysis,” *IEEE/ACM Transactions on Computational Biology & Bioinformatics*, vol. 9, no. 4, pp. 1106–1119, 2012.

[11] J. Wang, L. Wu, J. Kong, Y. Li, and B. Zhang, “Maximum weight and minimum redundancy: a novel framework for feature subset selection,” *Pattern Recognition*, vol. 46, no. 6, pp. 1616–1627, 2013.

[12] Y. Piao, M. Piao, K. Park, and K. H. Ryu, “An ensemble correlation-based gene selection algorithm for cancer classification with gene expression data,” *Bioinformatics*, vol. 28, no. 24, pp. 3306–3315, 2012.

[13] D. Zhang, S. Chen, and Z. Zhou, “Constraint score: a new filter method for feature selection with pairwise constraints,” *Pattern Recognition*, vol. 41, no. 5, pp. 1440–1451, 2008.

[14] X. Sun, Y. Liu, and L. An, “Ensemble dimensionality reduction and feature gene extraction for single-cell RNA-seq data,” *Nature Communications*, vol. 11, no. 1, p. 5853, 2020.

[15] R. Kohavi and G. John, “Artificial intelligence wrappers for feature subset selection,” *Cleve*, vol. 97, pp. 273–324, 1997.

[16] R. Diao, F. Chao, T. Peng, N. Snooke, and Q. Shen, “Feature selection inspired classifier ensemble reduction,” *IEEE Transactions on Cybernetics*, vol. 44, no. 8, pp. 1259–1268, 2014.

[17] A. A. Friedman, A. Letalı, D. E. Fisher, and K. T. Flaherty, “Precision medicine for cancer with next-generation functional diagnostics,” *Nature Reviews Cancer*, vol. 15, no. 12, pp. 747–756, 2015.

[18] F. Cheng, H. Liang, A. I. Butte, C. Eng, and R. Nussinov, “Personal mutanomes meet modern oncology drug discovery and precision health,” *Pharmacological Reviews*, vol. 71, no. 1, pp. 1–19, 2019.

[19] R. E. Banfield, L. O. Hall, K. W. Bowyer, and W. P. Kegelmeyer, “Ensemble diversity measures and their application to thinning,” *Information Fusion*, vol. 6, no. 1, pp. 49–62, 2005.

[20] T. Saegusa, Z. Zhao, H. Ke, Z. Ye, and T. Ma, “Detecting survival-associated biomarkers from heterogeneous populations,” *Scientific Reports*, vol. 11, no. 1, p. 3203, 2021.

[21] H. Sung, J. Ferlay, R. L. Siegel et al., “Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” *CA: A Cancer Journal for Clinicians*, vol. 71, no. 3, pp. 209–249, 2021.

[22] E. T. Kimchi, M. C. Posner, J. O. Park et al., “Progression of Barrett metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation,” *Cancer Research*, vol. 65, no. 8, pp. 3146–3154, 2005.

[23] S. Varambally, Y. Ju, B. Laxman et al., “Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression,” *Cancer Cell*, vol. 8, no. 5, pp. 393–406, 2005.

[24] A. Murat, E. Migliavacca, T. Gorlia, W. L. Lambiv, and M. E. Hegi, “Stem cell-related “self-renewal” signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma,” *Journal of Clinical Oncology*, vol. 26, no. 18, pp. 3015–3024, 2008.

[25] W. L. Lambiv, I. Vassallo, M. Delorenzi et al., “The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence,” *Neuro-Oncology*, vol. 13, no. 7, pp. 736–747, 2011.

[26] L. Scotto, G. Narayan, S. V. Nandula et al., “Identification of copy number gain and over-expressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression,” *Genes, Chromosomes & Cancer*, vol. 47, no. 9, pp. 755–765, 2008.

[27] M. Paoloni, S. Davis, S. Lana et al., “Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression,” *BMC Genomics*, vol. 10, no. 1, p. 625, 2009.
[28] S. C. Mok, T. Bonome, V. Vathipatiek al et al., “A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2,” Cancer Cell, vol. 16, no. 6, pp. 521–532, 2009.

[29] A. Sanchez-Palencia, M. Gomez-Morales, J. A. Gomez-Capilla et al., “Gene expression profiling reveals novel biomarkers in nonsmall cell lung cancer,” International Journal of Cancer International Du Cancer, vol. 129, no. 2, pp. 355–364, 2011.

[30] X. Chong, R. Peng, Y. Sun, L. Zhang, and Z. Zhang, “Identification of key genes in gastric cancer by bioinformatics analysis,” BioMed Research International, vol. 2020, no. 5, 2020.

[31] K. Dybkær, M. Bøgsted, S. Falgreen et al., “Diffuse large B–cell lymphoma classification system that associates normal B–cell subset phenotypes with prognosis,” Journal of Clinical Oncology, vol. 33, no. 12, pp. 1379–1388, 2015.

[32] C. H. Nørgaard, L. H. Jakobsen, A. J. Gentles, K. Dybkær, and S. Maubant, B. Tesson, V. Maire et al., “Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow—a proof of concept study,” Plos One, vol. 13, no. 3, p. e0193249, 2018.

[33] S. Maubant, B. Tessson, V. Maire et al., “Transcriptome analysis of Wnt3a-treated triple-negative breast cancer cells,” Plos One, vol. 10, no. 4, p. e0122333, 2015.

[34] V. Maire, F. Némati, M. Richardson et al., “Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer,” Cancer Research, vol. 73, no. 2, pp. 813–823, 2013.

[35] R. A. Irizarry, B. Hobbs, F. Collin et al., “Exploration, normalization, and summaries of high density oligonucleotide array probe level data,” Biostatistics, vol. 4, no. 2, pp. 249–264, 2003.

[36] A. Spooner, E. Chen, A. Sowmya et al., “A comparison of machine learning methods for survival analysis of high-dimensional clinical data for dementia prediction,” Scientific Reports, vol. 10, no. 1, p. 20410, 2020.

[37] H. Su, N. Hu, H. H. Yang, C. Wang, and P. R. Taylor, “Global gene expression profiling and validation in esophageal squamous cell carcinoma and its association with clinical phenotypes,” Clinical Cancer Research an Official Journal of the American Association for Cancer Research, vol. 17, no. 9, pp. 2955–2966, 2011.

[38] Q. Wang, C. Ma, and W. Kemmer, “Wdr66 is a novel marker for risk stratification and involved in epithelial-mesenchymal transition of esophageal squamous cell carcinoma,” BMC Cancer, vol. 13, no. 1, 2013.

[39] GEMO Study Collaborators, EBRACE Collaborators, KConFab Investigators et al., “Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes,” Nature Genetics, vol. 52, no. 1, pp. 56–73, 2020.

[40] P. A. Futreal, L. Coin, M. Marshall et al., “A census of human cancer genes,” Nature Reviews Cancer, vol. 4, no. 3, pp. 177–183, 2004.

[41] C. Turnbull, R. H. Scott, E. Thomas et al., “The 100 000 genomes project: bringing whole genome sequencing to the NHS,” BMJ (Clinical research ed.), vol. 361, p. k1687, 2018.

[42] S. Wu, Y. Liu-Chittenden, Y. Zheng, J. Dong, and D. J. Pan, “The TEAD/TEF family protein Scalloped mediates transcriptional output of the Hippo growth-regulatory pathway,” Developmental Cell, vol. 14, no. 3, pp. 388–398, 2008.

[43] S. K. Zaidi, A. J. Sullivan, R. Medina et al., “Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription,” The EMBO Journal, vol. 23, no. 4, pp. 790–799, 2004.

[44] A. Dhyani, A. S. S. Duarte, J. A. Machado-Neto, P. Favaro, M. M. Ortega, and S. T. O. Saad, “ANKHD1 regulates cell cycle progression and proliferation in multiple myeloma cells,” FEBS Letters, vol. 586, no. 24, pp. 4311–4318, 2012.

[45] M. Piccolella, V. Crippa, R. Cristofanii, P. Rusmini, and A. Poletti, “The small heat shock protein b8 (hspb8) modulates proliferation and migration of breast cancer cells,” Oncotarget, vol. 8, no. 6, pp. 10400–10415, 2017.

[46] M. Suzuki, R. Matsushima-Nishiwaki, G. Kuroyanagi et al., “Regulation by heat shock protein 22 (hsbp8) of transforming growth factor-a-induced ovary cancer cell migration,” Archives of Biochemistry and Biophysics, vol. 571, pp. 40–49, 2015.

[47] J. Shen, M. Li, and L. Min, “Hspb8 promotes cancer cell growth by activating the ERKCREB pathway and is indicative of a poor prognosis in gastric cancer patients,” Oncology Reports, vol. 39, no. 6, pp. 2978–2986, 2018.

[48] H. Fukushima, M. Yasumoto, S. Ogasawara et al., “ARHGEF15 overexpression worsens the prognosis in patients with pancreatic ductal adenocarcinoma through enhancing the motility and proliferative activity of the cancer cells,” Molecular Cancer, vol. 15, no. 1, pp. 1–13, 2016.

[49] M. Volpert, L. Furic, J. Hu et al., “CRISPR expression drives prostate cancer invasion and progression,” Endocrine Related Cancer, vol. 27, no. 7, pp. 415–430, 2020.

[50] Q. You, Y. Geng, H. Ye, G. Zhu, and H. Zhu, “HOPX is an epigenetically inactivated tumor suppressor and overexpression of HOPX induce apoptosis and cell cycle arrest in breast cancer,” Oncotargets and Therapy, vol. Volume 13, pp. 5955–5965, 2020.

[51] D. Yang, R. Li, J. Xia, W. Li, and H. Xue, “Long noncoding RNA PCAT18 upregulates SPRR3 to promote colorectal cancer progression by binding to mir-759,” Cancer Management and Research, vol. Volume 12, pp. 11445–11452, 2020.

[52] A. Nimmoconkar, D. Sanoudou, A. J. Butte et al., “Reproducibility of gene expression across generations of Affymetrix microarrays,” Bmc Bioinformatics, vol. 4, no. 1, p. 27, 2003.

[53] J. Zhang, D. Xu, K. Hao, Y. Zhang, and Y. D. Marinis, “FS-GBDT: identification multicancer-risk module via a feature selection algorithm by integrating Fisher score and gbdt,” Briefings in Bioinformatics, pp. 1–13, 2021.

[54] J. C. Mills and J. I. Gordon, “A new approach for filtering noise from high-density oligonucleotide microarray datasets,” Nucleic Acids Research, vol. 29, no. 15, p. 772, 2001.